fortress biotech, inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as fortress companies. the company will leverage its biopharmaceutical business expertise and drug development capabilities to help the fortress companies achieve their goals. additionally, the company will provide funding and management services to each of the fortress companies and from time to time the company and the fortress companies will seek licensing, partnerships, joint ventures, and/or public and private financings to accelerate and provide additional funding to support their research and development programs.
Company profile
Ticker
FBIO, FBIOP
Exchange
Website
CEO
Lindsay Rosenwald
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CORONADO BIOSCIENCES INC
SEC CIK
Corporate docs
Subsidiaries
Aevitas Therapeutics, Inc. • Avenue Therapeutics, Inc. • Cellvation, Inc. • Checkpoint Therapeutics, Inc. • Cyprium Therapeutics, Inc. • Helocyte, Inc. • Journey Medical Corporation • Mustang Bio, Inc. • Oncogenuity, Inc. • Urica Therapeutics, Inc. ...
IRS number
205157386
FBIO stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
424B3
Prospectus supplement
5 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
28 Mar 24
8-K
Departure of Directors or Certain Officers
26 Jan 24
8-K
Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
3 Jan 24
424B5
Prospectus supplement for primary offering
2 Jan 24
UPLOAD
Letter from SEC
30 Nov 23
8-K
Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
14 Nov 23
Latest ownership filings
SC 13D/A
AVENUE THERAPEUTICS, INC.
17 Apr 24
4
AVENUE THERAPEUTICS, INC.
17 Apr 24
4
David Jin
2 Apr 24
SC 13D/A
Checkpoint Therapeutics, Inc.
22 Mar 24
4
Checkpoint Therapeutics, Inc.
22 Mar 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
4
LINDSAY A MD ROSENWALD
9 Jan 24
4
Lucy Lu
3 Jan 24
4
Kevin Lorenz
3 Jan 24
4
J JAY LOBELL
3 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 74.75 mm | 74.75 mm | 74.75 mm | 74.75 mm | 74.75 mm | 74.75 mm |
Cash burn (monthly) | 4.82 mm | 11.32 mm | 4.59 mm | 14.78 mm | 5.59 mm | 11.76 mm |
Cash used (since last report) | 32.76 mm | 76.92 mm | 31.16 mm | 100.44 mm | 38.01 mm | 79.92 mm |
Cash remaining | 41.98 mm | -2.17 mm | 43.58 mm | -25.69 mm | 36.74 mm | -5.18 mm |
Runway (months of cash) | 8.7 | -0.2 | 9.5 | -1.7 | 6.6 | -0.4 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 48 |
Opened positions | 7 |
Closed positions | 8 |
Increased positions | 10 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 6.03 bn |
Total shares | 25.96 mm |
Total puts | 2.30 k |
Total calls | 121.60 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Katz Daryl | 6.05 mm | $4.60 mm |
Nantahala Capital Management | 6.02 mm | $1.75 bn |
Vanguard | 5.26 mm | $1.53 bn |
Opaleye Management | 2.00 mm | $580.60 mm |
Wealth Enhancement Advisory Services | 1.54 mm | $447.64 mm |
BLK Blackrock | 1.12 mm | $326.33 mm |
Acadian Asset Management | 1.08 mm | $311.00 k |
Geode Capital Management | 900.40 k | $261.46 mm |
Renaissance Technologies | 323.63 k | $94.00 k |
STT State Street | 277.01 k | $80.42 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Apr 24 | Fortress Biotech | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 413,507 | 0.00 | 3,547,393 |
1 Apr 24 | David Jin | COMMON STOCK, PAR VALUE $0.001 | Grant | Acquire A | No | No | 1.7 | 2,352 | 4.00 k | 238,268 |
20 Mar 24 | Fortress Biotech | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 193,905 | 0.00 | 2,096,278 |
5 Jan 24 | Rosenwald Lindsay A MD | COMMON STOCK, PAR VALUE $0.001 | Buy | Acquire P | No | No | 2.3754 | 50,000 | 118.77 k | 2,863,905 |
2 Jan 24 | Fortress Biotech | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 2,101,496 | 0.00 | 3,133,886 |
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
17 Apr 24
Fortress Biotech Q4 EPS $(0.53) Beats $(1.97) Estimate, Sales $19.95M Beat $14.89M Estimate
28 Mar 24
Alliance Global Partners Initiates Coverage On Fortress Biotech with Buy Rating, Announces Price Target of $5
19 Mar 24
Roth MKM Reinstates Buy on Fortress Biotech, Announces $10 Price Target
15 Mar 24
Phase 1 CAR T Cell Therapy Trial For Glioblastoma At City Of Hope, Demonstrates Clinical Activity Against Incurable Brain Tumors, The IL13Rα2-Targeting CAR T Cell Is Exclusively Licensed By Mustang Bio, A Fortress Biotech Company
7 Mar 24
Press releases
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
28 Mar 24
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
25 Mar 24
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
22 Mar 24
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
21 Mar 24
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
18 Mar 24